The Michael J. Fox Foundation awarded $10.1 million for five new clinical studies and 14 pre-clinical therapeutic development projects. The funding aims to improve treatment regimens for Parkinson's patients, reduce complications, and develop novel therapies.
The Michael J. Fox Foundation has awarded $1.1 million for 15 high-risk, high-reward research projects to explore new approaches to treating Parkinson's disease using gene silencing techniques and induced pluripotent stem cell technology. The funding aims to develop transformative treatments and a cure for PD.
The Michael J. Fox Foundation has awarded $2.4 million to nine research teams to validate potential therapeutic targets for Parkinson's disease. The funding aims to accumulate evidence and reduce the risk of investment for industry, ultimately accelerating PD drug development.
The Michael J. Fox Foundation has awarded $5.6 million for a Phase 2 clinical trial investigating the potential of inosine to slow or stop Parkinson's disease progression. The study will determine the safety of using inosine to raise urate levels and assess optimal dosage for therapeutic effect.
The Michael J. Fox Foundation has awarded up to $3 million in funding to four industry teams as part of its Therapeutics Development Initiative, focusing on treatments targeting alpha-synuclein toxicity, chronic inflammation, trophic factors, and mitochondrial dysfunction. The grants aim to accelerate the development and delivery of tr...